Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab

Table 3

Results of separate subgroups of group B before and six months after initiation of treatment; mean number of affected peripheral (PS) and central segments (CS) of neovascularization; corrected distance visual acuity (CDVA).

					6 months after treatment (1 month in group 4)
		CDVA	PS	CS	CDVA	PS	CS	𝑃
1	Pterygium (𝑛=12)	1.0 (±0.02)	12.75 (±9.91)	0.25 (±0.82)	1.0 (±0.02)	9.0 (±4.08)	0	PS: 0.003
								CS: 0.000
2	NV after penetrating keratoplasty (𝑛=6)	0.06 (±0.04)	35.5 (±20.13)	0.83 (±1.21)	0.12 (±0.13)	28.0 (±23.12)	0.33 (±0.74)	PS: 0.002
								CS: 0.000
3	Other etiologies (𝑛=15)	0.58 (±0.32)	37.0 (±21.49)	3.4 (±4.01)	0.59 (±0.32)	29.53 (±18.73)	2.53 (±3.98)	PS: 0.000
								CS: 0.000
4	Preparation for penetrating keratoplasty (𝑛=5)	0.05 (±0.07)	28.2 (±12.37)	10.8 (±6.65)	0.05 (±0.08)	20.40 (±14.25)	6.0 (±5.62)	PS: 0.02
								CS: 0.001